Atopic Dermatitis
Conditions
Brief summary
Primary Objective: To evaluate the efficacy of dupilumab monotherapy compared to placebo treatment in adult participants with moderate-to-severe atopic dermatitis (AD). Secondary Objectives: * To evaluate the safety of dupilumab monotherapy compared to placebo treatment in adult participants with moderate-to-severe AD. * To evaluate the effect of dupilumab on improving patient reported outcomes (PROs). * To evaluate dupilumab immunogenicity.
Detailed description
The maximum study duration was 33 weeks per participants, including a screening period of up to 5 weeks, a 16-week randomized treatment period, and a 12-week follow-up period.
Interventions
DRUGDupilumab
Pharmaceutical form: solution, Route of administration: SC
DRUGPlacebo
Pharmaceutical form: solution, Route of administration: SC
DRUGEmollient (moisturizer)
Pharmaceutical form: cream, Route of administration: topical use
Sponsors
Regeneron Pharmaceuticals
Sanofi
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female, 18 years or older. * AD (according to American Academy of Dermatology Consensus Criteria, 2014) that had been present for at least 3 years before the screening visit. * Eczema Area and Severity Index (EASI) score greater than or equal to (\>=) 16 at the screening and baseline visits. * Investigator's Global Assessment (IGA) score \>=3 (on the 0 to 4 IGA scale, in which 3 was moderate and 4 was severe) at the screening and baseline visits. * Participants with \>=10 percent (%) body surface area (BSA) of AD involvement at the screening and baseline visits. * Baseline Pruritus Numerical Rating Scale (NRS) average score for maximum itch intensity \>=4. * Documented recent history (within 6 months before the screening visit) of inadequate response to treatment with topical medications or for whom topical treatments were otherwise medically inadvisable (e.g., because of important side effects or safety risks).
Exclusion criteria
* Had used any of the following treatments within 4 weeks before the baseline visit, or any condition that, in the opinion of the investigator, was likely to require such treatment(s) during the first 4 weeks of study treatment: * Immunosuppressive/immunomodulating drugs (e.g., systemic corticosteroids, cyclosporine, mycophenolate-mofetil, interferon-gamma \[IFN-γ\], Janus kinase inhibitors, azathioprine, methotrexate); * Phototherapy for AD. * Treatment with topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) within 1 week before the baseline visit. * Treatment with systemic Traditional Chinese Medicine (TCM) within 4 weeks before the baseline visit or treatment with topical TCM within 1 week before the baseline visit. * Treatment with biologics as follows: * Any cell-depleting agents including but not limited to rituximab: within 6 months before the baseline visit, or until lymphocyte count returns to normal, whichever is longer; * Other biologics: within 5 half-lives (if known) or 16 weeks prior to baseline visit, whichever was longer. * Initiation of treatment of AD with prescription moisturizers or moisturizers containing additives such as ceramide, hyaluronic acid, urea, or filaggrin degradation products during the screening period (participants may continue using stable doses of such moisturizers if initiated before the screening visit). * Regular use (more than 2 visits per week) of a tanning booth/parlor within 4 weeks of the baseline visit. * Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit. * Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before the baseline visit, or superficial skin infections within 1 week before the baseline visit. NOTE: participants may be rescreened after infection resolves. * Known or suspected history of immunosuppression, including history of invasive opportunistic infections (e.g., tuberculosis \[TB\], histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis) despite infection resolution: or unusually frequent, recurrent, or prolonged infections, per investigator judgment. * Active TB, latent untreated TB or a history of incompletely treated TB or non-tuberculous mycobacterial infection were excluded from the study unless that was well documented by a specialist that the participants had adequately treated and could then start treatment with a biologic agent, in the medical judgment of the Investigator and/or infectious disease specialist. TB testing would be performed according to local guidelines if required by regulatory authorities or ethics committees. The above information was not intended to contain all considerations relevant to a participants potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Investigator's Global Assessment (IGA) Score of 0 or 1 and Reduction From Baseline of Greater Than or Equal to (>=) 2 Points at Week 16 | Baseline, Week 16 | The IGA is an assessment instrument used to rate the severity of AD globally based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Who Achieved >=4 Points With Reduction From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score at Week 16 | Baseline, Week 16 | Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity. |
| Number of Participants Who Achieved >=3 Points With Reduction From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale Score at Week 16 | Baseline, Week 16 | Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity. |
| Percentage Change From Baseline at Week 16 in Weekly Average of Peak Daily Pruritus NRS | Baseline, Week 16 | Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity. |
| Change From Baseline at Week 16 in Weekly Average of Peak Daily Pruritus NRS | Baseline, Week 16 | Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity. |
| Percentage Change From Baseline to Week 16 in EASI Score | Baseline to Week 16 | EASI: Measure to assess severity & extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] & lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of 0 (absent) through 3(severe) & scored separately for each of 4 body regions (head, trunk, upper & lower extremities). Total score ranges from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD. |
| Change From Baseline to Week 16 in Percent Body Surface Area (BSA) of AD Involvement | Baseline to Week 16 | BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]) and reported as a percentage of all major body sections combined. The reported percentage of BSA was combined percentage of all major body sections. |
| Change From Baseline to Week 16 in Dermatology Life Quality Index (DLQI) Total Score | Baseline to Week 16 | The DLQI was a validated questionnaire used to measure the impact of AD disease symptoms and treatment on health-related quality of life (QOL). DLQI consisting of a set of 10 questions which assess QOL over the past week. Responses to each questions were assessed on a scale of 0 to 3, where 0 is not at all and 3 is very much. Scores from all 10 questions added up to give total DLQI scores ranged from 0 (not at all) to 30 (very much), higher scores indicated more impact on quality of life. |
| Change From Baseline to Week 16 in Patient Oriented Eczema Measure (POEM) | Baseline to Week 16 | The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms on a scale ranging from 0 to 4 (0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, 4 = all days). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). Higher scores indicated more severe disease and poor quality of life. |
| Percentage Change From Baseline to Week 2 in Weekly Average of Peak Daily Pruritus NRS | Baseline to Week 2 | Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity. |
| Percentage Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire (EQ-5D) Index Scores | Baseline to Week 16 | The EQ-5D is a standardized measure of health status which is consists of 2 parts; the descriptive system and the EQ visual analogue scale (EQVAS). The EQ-5D descriptive system includes 5 dimensions; mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension measured on 3 levels: no problem (level 1), some problems (level 2), extreme problems (level 3). The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state. The 5 dimensional 3-level systems was converted into single index utility score between 0 to 1 that quantify health status, where 0 represents death and 1 represents perfect health. |
| Percentage Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire Visual Analog Scale Scores | Baseline to Week 16 | The EQ-5D VAS records the respondent's self-rated health on a vertical, visual analogue scale ranged from 0-100 where 100 indicated best imaginable health state and 0 indicated worst imaginable health state, higher scores indicated better outcome. |
| Absolute Change From Baseline to Week 16 in EQ-5D Index Scores | Baseline to Week 16 | The EQ-5D is a standardized measure of health status which consisted of 2 parts; the descriptive system and the EQVAS. The EQ-5D descriptive system includes 5 dimensions; mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension measured on 3 levels: no problem (level 1), some problems (level 2), extreme problems (level 3). The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state. The 5 dimensional 3-level systems was converted into single index utility score between 0 to 1 that quantify health status, where 0 represents death and 1 represents perfect health. |
| Number of Participants With Eczema Area and Severity Index (EASI) - 75 Response (>= 75% Reduction in Score From Baseline) at Week 16 | Baseline, Week 16 | EASI: Measure to assess severity and extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] and lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of 0 (absent) through 3 (severe) and scored separately for each of 4 body regions (head, trunk, upper and lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD. |
| Number of Participants Who Achieve Reduction of IGA Score by >=2 From Baseline to Week 16 | Baseline to Week 16 | The IGA is an assessment instrument used to rate the severity of AD globally, based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity. In this outcome measure, number of participants who achieved reduction from baseline of \>=2 points in IGA score at Week 16 were reported. |
| Number of Participants Achieving IGA 0 to 1 and a Reduction of >=2 Points From Baseline Through Week 16 | Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 | The IGA is an assessment instrument used to rate the severity of AD globally based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity. |
| Absolute Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16 | Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 | EASI: Measure to assess severity & extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] & lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of 0 (absent) through 3 (severe) & scored separately for each of 4 body regions (head, trunk, upper & lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD. Participants with missing EASI Score at each visit were imputed using MI (Multiple Imputation) method. |
| Percentage Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16 | Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 | EASI: Measure to assess severity & extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] & lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of 0 (absent) through 3 (severe) & scored separately for each of 4 body regions (head, trunk, upper & lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD. |
| Number of Participants With EASI-50 (>=50% Improvement From Baseline) at Week 16 | Baseline, Week 16 | EASI: Measure to assess severity & extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] & lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of 0 (absent) through 3 (severe) & scored separately for each of 4 body regions (head, trunk, upper & lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD. |
| Number of Participants With EASI-90 (>=90% Improvement From Baseline) at Week 16 | Baseline, Week 16 | EASI: Measure to assess severity & extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] & lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of 0 (absent) through 3 (severe) & scored separately for each of 4 body regions (head, trunk, upper & lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD. |
| Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | From Baseline Through Week 16 | Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity. Participants with missing Peak Daily Pruritus NRS Score at each visit were imputed using MI method. |
| Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | From Baseline Through Week 16 | Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity. Participants with missing peak NRS scores at each visit were imputed using MI method. |
| Number of Participants Who Responded Absence of Pruritus or Mild Pruritus in the Pruritus Categorical Scale at Week 16 | Week 16 | The pruritus categorical scale was a 4-point scale used to assess symptoms of AD. The scale is rated as follows: 0: absence of pruritus; 1: mild pruritus (occasional slight itching/scratching); 2: moderate pruritus (constant or intermittent itching/scratching that does not disturb sleep) and 3: severe pruritus (bothersome itching/scratching that disturbs sleep), higher scores indicated worse outcome. |
| Number of Days of Sick Leave/Missed School Days | Week 16 | Participants who were employed or enrolled in school for full time were asked to report the number of sick leave/missed school days since the last study assessment. Participants were counted as Full time if the participant checked Full time at all visits through 16-week treatment period and participants were counted as Part time if the participant checked at least one Part time during 16-week treatment period. |
| Percentage of Participants With at Least One Day Sick Leave/Missed School Days | Week 16 | Participants who were employed or enrolled in school for full time were asked to report the number of sick leave/missed school days since the last study assessment. Participants were counted as Full time if the participant checked Full time at all visits through 16-week treatment period and participants were counted as Part time if the participant checked at least one Part time during 16-week treatment period. |
| Absolute Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire Visual Analog Scale Scores | Baseline to Week 16 | The EQ-5D VAS records the respondent's self-rated health on a vertical, visual analogue scale ranged from 0-100 where 100 indicated best imaginable health state and 0 indicated worst imaginable health state, higher scores indicated better outcome. |
Countries
China
Participant flow
Recruitment details
The study was conducted at 25 active centers in China between 19 Dec 2018 and 14 Feb 2020. A total of 165 participants were randomized and treated in the study.
Pre-assignment details
Participants were randomized in a 1:1 ratio to dupilumab or placebo according to a central randomization scheme provided by an interactive response technology.
Participants by arm
| Arm | Count |
|---|---|
| Placebo Q2W Placebo matched to dupilumab 600 mg (loading dose), SC on Day 1 followed by placebo matched to dupilumab 300 mg Q2W for 16 weeks. | 83 |
| Dupilumab 300 mg Q2W Dupilumab at a loading dose of 600 mg, SC on Day 1 followed by 300 mg, Q2W for 16 weeks. | 82 |
| Total | 165 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event (AE) | 2 | 4 |
| Overall Study | Lack of Efficacy | 4 | 1 |
| Overall Study | Withdrawal by Subject | 11 | 1 |
Baseline characteristics
| Characteristic | Dupilumab 300 mg Q2W | Total | Placebo Q2W |
|---|---|---|---|
| Age, Continuous | 31.0 years STANDARD_DEVIATION 10.47 | 30.6 years STANDARD_DEVIATION 11.49 | 30.2 years STANDARD_DEVIATION 12.46 |
| Investigator's Global Assessment (IGA) Score IGA = 3 | 35 Participants | 72 Participants | 37 Participants |
| Investigator's Global Assessment (IGA) Score IGA = 4 | 47 Participants | 93 Participants | 46 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 82 Participants | 165 Participants | 83 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Female | 24 Participants | 47 Participants | 23 Participants |
| Sex: Female, Male Male | 58 Participants | 118 Participants | 60 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 83 | 0 / 82 |
| other Total, other adverse events | 57 / 83 | 56 / 82 |
| serious Total, serious adverse events | 4 / 83 | 1 / 82 |
Outcome results
Primary
Number of Participants With Investigator's Global Assessment (IGA) Score of 0 or 1 and Reduction From Baseline of Greater Than or Equal to (>=) 2 Points at Week 16
The IGA is an assessment instrument used to rate the severity of AD globally based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity.
Time frame: Baseline, Week 16
Population: Analysis was performed on ITT population.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo Q2W | Number of Participants With Investigator's Global Assessment (IGA) Score of 0 or 1 and Reduction From Baseline of Greater Than or Equal to (>=) 2 Points at Week 16 | 4 Participants |
| Dupilumab 300 mg Q2W | Number of Participants With Investigator's Global Assessment (IGA) Score of 0 or 1 and Reduction From Baseline of Greater Than or Equal to (>=) 2 Points at Week 16 | 22 Participants |
p-value: <0.000195% CI: [11.37, 32.65]Cochran-Mantel-Haenszel
Secondary
Absolute Change From Baseline to Week 16 in EQ-5D Index Scores
The EQ-5D is a standardized measure of health status which consisted of 2 parts; the descriptive system and the EQVAS. The EQ-5D descriptive system includes 5 dimensions; mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension measured on 3 levels: no problem (level 1), some problems (level 2), extreme problems (level 3). The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state. The 5 dimensional 3-level systems was converted into single index utility score between 0 to 1 that quantify health status, where 0 represents death and 1 represents perfect health.
Time frame: Baseline to Week 16
Population: Analysis was performed on ITT population.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo Q2W | Absolute Change From Baseline to Week 16 in EQ-5D Index Scores | 0.02 units on a scale | Standard Error 0.006 |
| Dupilumab 300 mg Q2W | Absolute Change From Baseline to Week 16 in EQ-5D Index Scores | 0.06 units on a scale | Standard Error 0.004 |
Secondary
Absolute Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire Visual Analog Scale Scores
The EQ-5D VAS records the respondent's self-rated health on a vertical, visual analogue scale ranged from 0-100 where 100 indicated best imaginable health state and 0 indicated worst imaginable health state, higher scores indicated better outcome.
Time frame: Baseline to Week 16
Population: Analysis was performed on ITT population.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo Q2W | Absolute Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire Visual Analog Scale Scores | 10.75 units on a scale | Standard Error 2.689 |
| Dupilumab 300 mg Q2W | Absolute Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire Visual Analog Scale Scores | 18.22 units on a scale | Standard Error 2.243 |
Secondary
Absolute Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16
EASI: Measure to assess severity & extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] & lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of 0 (absent) through 3 (severe) & scored separately for each of 4 body regions (head, trunk, upper & lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD. Participants with missing EASI Score at each visit were imputed using MI (Multiple Imputation) method.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Population: Analysis was performed on ITT population.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Q2W | Absolute Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16 | Week 4 | -6.45 units on a scale | Standard Deviation 11.838 |
| Placebo Q2W | Absolute Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16 | Week 12 | -11.23 units on a scale | Standard Deviation 12.603 |
| Placebo Q2W | Absolute Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16 | Week 8 | -9.54 units on a scale | Standard Deviation 10.947 |
| Placebo Q2W | Absolute Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16 | Week 16 | -12.60 units on a scale | Standard Deviation 12.484 |
| Placebo Q2W | Absolute Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16 | Week 2 | -3.27 units on a scale | Standard Deviation 7.974 |
| Dupilumab 300 mg Q2W | Absolute Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16 | Week 16 | -25.87 units on a scale | Standard Deviation 13.985 |
| Dupilumab 300 mg Q2W | Absolute Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16 | Week 2 | -12.48 units on a scale | Standard Deviation 12.64 |
| Dupilumab 300 mg Q2W | Absolute Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16 | Week 4 | -19.56 units on a scale | Standard Deviation 13.687 |
| Dupilumab 300 mg Q2W | Absolute Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16 | Week 8 | -22.45 units on a scale | Standard Deviation 12.83 |
| Dupilumab 300 mg Q2W | Absolute Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16 | Week 12 | -24.32 units on a scale | Standard Deviation 14.191 |
Secondary
Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity. Participants with missing Peak Daily Pruritus NRS Score at each visit were imputed using MI method.
Time frame: From Baseline Through Week 16
Population: Analysis was performed on ITT population.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 1 | -0.26 units on a scale | Standard Error 0.106 |
| Placebo Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 2 | -0.38 units on a scale | Standard Error 0.135 |
| Placebo Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 3 | -0.61 units on a scale | Standard Error 0.153 |
| Placebo Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 4 | -0.69 units on a scale | Standard Error 0.162 |
| Placebo Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 5 | -0.88 units on a scale | Standard Error 0.191 |
| Placebo Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 6 | -0.96 units on a scale | Standard Error 0.205 |
| Placebo Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 7 | -0.88 units on a scale | Standard Error 0.214 |
| Placebo Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 8 | -1.04 units on a scale | Standard Error 0.212 |
| Placebo Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 9 | -1.10 units on a scale | Standard Error 0.218 |
| Placebo Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 10 | -1.12 units on a scale | Standard Error 0.221 |
| Placebo Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 11 | -1.24 units on a scale | Standard Error 0.231 |
| Placebo Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 12 | -1.34 units on a scale | Standard Error 0.233 |
| Placebo Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 13 | -1.46 units on a scale | Standard Error 0.246 |
| Placebo Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 14 | -1.53 units on a scale | Standard Error 0.264 |
| Placebo Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 15 | -1.56 units on a scale | Standard Error 0.262 |
| Placebo Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 16 | -1.64 units on a scale | Standard Error 0.272 |
| Dupilumab 300 mg Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 16 | -3.84 units on a scale | Standard Error 0.237 |
| Dupilumab 300 mg Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 1 | -0.63 units on a scale | Standard Error 0.107 |
| Dupilumab 300 mg Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 9 | -3.29 units on a scale | Standard Error 0.209 |
| Dupilumab 300 mg Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 2 | -1.26 units on a scale | Standard Error 0.136 |
| Dupilumab 300 mg Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 13 | -3.65 units on a scale | Standard Error 0.223 |
| Dupilumab 300 mg Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 3 | -1.90 units on a scale | Standard Error 0.153 |
| Dupilumab 300 mg Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 10 | -3.38 units on a scale | Standard Error 0.21 |
| Dupilumab 300 mg Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 4 | -2.26 units on a scale | Standard Error 0.159 |
| Dupilumab 300 mg Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 15 | -3.81 units on a scale | Standard Error 0.234 |
| Dupilumab 300 mg Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 5 | -2.61 units on a scale | Standard Error 0.187 |
| Dupilumab 300 mg Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 11 | -3.52 units on a scale | Standard Error 0.216 |
| Dupilumab 300 mg Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 6 | -2.81 units on a scale | Standard Error 0.201 |
| Dupilumab 300 mg Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 14 | -3.71 units on a scale | Standard Error 0.241 |
| Dupilumab 300 mg Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 7 | -3.14 units on a scale | Standard Error 0.208 |
| Dupilumab 300 mg Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 12 | -3.59 units on a scale | Standard Error 0.213 |
| Dupilumab 300 mg Q2W | Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 8 | -3.21 units on a scale | Standard Error 0.205 |
Secondary
Change From Baseline at Week 16 in Weekly Average of Peak Daily Pruritus NRS
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.
Time frame: Baseline, Week 16
Population: Analysis was performed on ITT population.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo Q2W | Change From Baseline at Week 16 in Weekly Average of Peak Daily Pruritus NRS | -1.64 units on a scale | Standard Error 0.272 |
| Dupilumab 300 mg Q2W | Change From Baseline at Week 16 in Weekly Average of Peak Daily Pruritus NRS | -3.84 units on a scale | Standard Error 0.237 |
Secondary
Change From Baseline to Week 16 in Dermatology Life Quality Index (DLQI) Total Score
The DLQI was a validated questionnaire used to measure the impact of AD disease symptoms and treatment on health-related quality of life (QOL). DLQI consisting of a set of 10 questions which assess QOL over the past week. Responses to each questions were assessed on a scale of 0 to 3, where 0 is not at all and 3 is very much. Scores from all 10 questions added up to give total DLQI scores ranged from 0 (not at all) to 30 (very much), higher scores indicated more impact on quality of life.
Time frame: Baseline to Week 16
Population: Analysis was performed on ITT population.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo Q2W | Change From Baseline to Week 16 in Dermatology Life Quality Index (DLQI) Total Score | -5.06 units on a scale | Standard Error 0.701 |
| Dupilumab 300 mg Q2W | Change From Baseline to Week 16 in Dermatology Life Quality Index (DLQI) Total Score | -10.33 units on a scale | Standard Error 0.625 |
Secondary
Change From Baseline to Week 16 in Patient Oriented Eczema Measure (POEM)
The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms on a scale ranging from 0 to 4 (0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, 4 = all days). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). Higher scores indicated more severe disease and poor quality of life.
Time frame: Baseline to Week 16
Population: Analysis was performed on ITT population.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo Q2W | Change From Baseline to Week 16 in Patient Oriented Eczema Measure (POEM) | -4.04 units on a scale | Standard Error 0.788 |
| Dupilumab 300 mg Q2W | Change From Baseline to Week 16 in Patient Oriented Eczema Measure (POEM) | -12.89 units on a scale | Standard Error 0.685 |
Secondary
Change From Baseline to Week 16 in Percent Body Surface Area (BSA) of AD Involvement
BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]) and reported as a percentage of all major body sections combined. The reported percentage of BSA was combined percentage of all major body sections.
Time frame: Baseline to Week 16
Population: Analysis was performed on ITT population.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo Q2W | Change From Baseline to Week 16 in Percent Body Surface Area (BSA) of AD Involvement | -19.25 percentage of body surface area | Standard Error 2.557 |
| Dupilumab 300 mg Q2W | Change From Baseline to Week 16 in Percent Body Surface Area (BSA) of AD Involvement | -37.76 percentage of body surface area | Standard Error 2.126 |
Secondary
Number of Days of Sick Leave/Missed School Days
Participants who were employed or enrolled in school for full time were asked to report the number of sick leave/missed school days since the last study assessment. Participants were counted as Full time if the participant checked Full time at all visits through 16-week treatment period and participants were counted as Part time if the participant checked at least one Part time during 16-week treatment period.
Time frame: Week 16
Population: Analysis was performed on ITT population. Here, 'overall number of participants analyzed' = participants with available data for this outcome measure and 'number analyzed' represent the number of participants analyzed for each specified row.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Q2W | Number of Days of Sick Leave/Missed School Days | Full time | 0.66 Days | Standard Deviation 2.075 |
| Placebo Q2W | Number of Days of Sick Leave/Missed School Days | Part time | 11.14 Days | Standard Deviation 20.923 |
| Dupilumab 300 mg Q2W | Number of Days of Sick Leave/Missed School Days | Full time | 0.88 Days | Standard Deviation 3.468 |
| Dupilumab 300 mg Q2W | Number of Days of Sick Leave/Missed School Days | Part time | 7.44 Days | Standard Deviation 9.202 |
Secondary
Number of Participants Achieving IGA 0 to 1 and a Reduction of >=2 Points From Baseline Through Week 16
The IGA is an assessment instrument used to rate the severity of AD globally based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Population: Analysis was performed on ITT population.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Placebo Q2W | Number of Participants Achieving IGA 0 to 1 and a Reduction of >=2 Points From Baseline Through Week 16 | Week 4 | 0 Participants |
| Placebo Q2W | Number of Participants Achieving IGA 0 to 1 and a Reduction of >=2 Points From Baseline Through Week 16 | Week 12 | 4 Participants |
| Placebo Q2W | Number of Participants Achieving IGA 0 to 1 and a Reduction of >=2 Points From Baseline Through Week 16 | Week 8 | 0 Participants |
| Placebo Q2W | Number of Participants Achieving IGA 0 to 1 and a Reduction of >=2 Points From Baseline Through Week 16 | Week 16 | 4 Participants |
| Placebo Q2W | Number of Participants Achieving IGA 0 to 1 and a Reduction of >=2 Points From Baseline Through Week 16 | Week 2 | 0 Participants |
| Dupilumab 300 mg Q2W | Number of Participants Achieving IGA 0 to 1 and a Reduction of >=2 Points From Baseline Through Week 16 | Week 16 | 22 Participants |
| Dupilumab 300 mg Q2W | Number of Participants Achieving IGA 0 to 1 and a Reduction of >=2 Points From Baseline Through Week 16 | Week 2 | 2 Participants |
| Dupilumab 300 mg Q2W | Number of Participants Achieving IGA 0 to 1 and a Reduction of >=2 Points From Baseline Through Week 16 | Week 4 | 6 Participants |
| Dupilumab 300 mg Q2W | Number of Participants Achieving IGA 0 to 1 and a Reduction of >=2 Points From Baseline Through Week 16 | Week 8 | 9 Participants |
| Dupilumab 300 mg Q2W | Number of Participants Achieving IGA 0 to 1 and a Reduction of >=2 Points From Baseline Through Week 16 | Week 12 | 16 Participants |
Secondary
Number of Participants Who Achieved >=3 Points With Reduction From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale Score at Week 16
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.
Time frame: Baseline, Week 16
Population: Analysis was performed on ITT population.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo Q2W | Number of Participants Who Achieved >=3 Points With Reduction From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale Score at Week 16 | 8 Participants |
| Dupilumab 300 mg Q2W | Number of Participants Who Achieved >=3 Points With Reduction From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale Score at Week 16 | 43 Participants |
Secondary
Number of Participants Who Achieved >=4 Points With Reduction From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score at Week 16
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.
Time frame: Baseline, Week 16
Population: Analysis was performed on ITT population.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo Q2W | Number of Participants Who Achieved >=4 Points With Reduction From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score at Week 16 | 4 Participants |
| Dupilumab 300 mg Q2W | Number of Participants Who Achieved >=4 Points With Reduction From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score at Week 16 | 32 Participants |
Secondary
Number of Participants Who Achieve Reduction of IGA Score by >=2 From Baseline to Week 16
The IGA is an assessment instrument used to rate the severity of AD globally, based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity. In this outcome measure, number of participants who achieved reduction from baseline of \>=2 points in IGA score at Week 16 were reported.
Time frame: Baseline to Week 16
Population: Analysis was performed on ITT population.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo Q2W | Number of Participants Who Achieve Reduction of IGA Score by >=2 From Baseline to Week 16 | 7 Participants |
| Dupilumab 300 mg Q2W | Number of Participants Who Achieve Reduction of IGA Score by >=2 From Baseline to Week 16 | 39 Participants |
Secondary
Number of Participants Who Responded Absence of Pruritus or Mild Pruritus in the Pruritus Categorical Scale at Week 16
The pruritus categorical scale was a 4-point scale used to assess symptoms of AD. The scale is rated as follows: 0: absence of pruritus; 1: mild pruritus (occasional slight itching/scratching); 2: moderate pruritus (constant or intermittent itching/scratching that does not disturb sleep) and 3: severe pruritus (bothersome itching/scratching that disturbs sleep), higher scores indicated worse outcome.
Time frame: Week 16
Population: Analysis was performed on ITT population.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo Q2W | Number of Participants Who Responded Absence of Pruritus or Mild Pruritus in the Pruritus Categorical Scale at Week 16 | 12 Participants |
| Dupilumab 300 mg Q2W | Number of Participants Who Responded Absence of Pruritus or Mild Pruritus in the Pruritus Categorical Scale at Week 16 | 49 Participants |
Secondary
Number of Participants With EASI-50 (>=50% Improvement From Baseline) at Week 16
EASI: Measure to assess severity & extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] & lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of 0 (absent) through 3 (severe) & scored separately for each of 4 body regions (head, trunk, upper & lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD.
Time frame: Baseline, Week 16
Population: Analysis was performed on ITT population.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo Q2W | Number of Participants With EASI-50 (>=50% Improvement From Baseline) at Week 16 | 24 Participants |
| Dupilumab 300 mg Q2W | Number of Participants With EASI-50 (>=50% Improvement From Baseline) at Week 16 | 58 Participants |
Secondary
Number of Participants With EASI-90 (>=90% Improvement From Baseline) at Week 16
EASI: Measure to assess severity & extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] & lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of 0 (absent) through 3 (severe) & scored separately for each of 4 body regions (head, trunk, upper & lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD.
Time frame: Baseline, Week 16
Population: Analysis was performed on ITT population.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo Q2W | Number of Participants With EASI-90 (>=90% Improvement From Baseline) at Week 16 | 5 Participants |
| Dupilumab 300 mg Q2W | Number of Participants With EASI-90 (>=90% Improvement From Baseline) at Week 16 | 33 Participants |
Secondary
Number of Participants With Eczema Area and Severity Index (EASI) - 75 Response (>= 75% Reduction in Score From Baseline) at Week 16
EASI: Measure to assess severity and extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] and lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of 0 (absent) through 3 (severe) and scored separately for each of 4 body regions (head, trunk, upper and lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD.
Time frame: Baseline, Week 16
Population: Analysis was performed on ITT population.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo Q2W | Number of Participants With Eczema Area and Severity Index (EASI) - 75 Response (>= 75% Reduction in Score From Baseline) at Week 16 | 12 Participants |
| Dupilumab 300 mg Q2W | Number of Participants With Eczema Area and Severity Index (EASI) - 75 Response (>= 75% Reduction in Score From Baseline) at Week 16 | 47 Participants |
Secondary
Percentage Change From Baseline at Week 16 in Weekly Average of Peak Daily Pruritus NRS
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.
Time frame: Baseline, Week 16
Population: Analysis was performed on ITT population.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo Q2W | Percentage Change From Baseline at Week 16 in Weekly Average of Peak Daily Pruritus NRS | -21.13 percentage change | Standard Error 3.61 |
| Dupilumab 300 mg Q2W | Percentage Change From Baseline at Week 16 in Weekly Average of Peak Daily Pruritus NRS | -48.59 percentage change | Standard Error 3.026 |
Secondary
Percentage Change From Baseline to Week 16 in EASI Score
EASI: Measure to assess severity & extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] & lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of 0 (absent) through 3(severe) & scored separately for each of 4 body regions (head, trunk, upper & lower extremities). Total score ranges from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD.
Time frame: Baseline to Week 16
Population: Analysis was performed on ITT population.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo Q2W | Percentage Change From Baseline to Week 16 in EASI Score | -39.44 percentage change | Standard Error 4.936 |
| Dupilumab 300 mg Q2W | Percentage Change From Baseline to Week 16 in EASI Score | -75.23 percentage change | Standard Error 3.879 |
Secondary
Percentage Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire (EQ-5D) Index Scores
The EQ-5D is a standardized measure of health status which is consists of 2 parts; the descriptive system and the EQ visual analogue scale (EQVAS). The EQ-5D descriptive system includes 5 dimensions; mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension measured on 3 levels: no problem (level 1), some problems (level 2), extreme problems (level 3). The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state. The 5 dimensional 3-level systems was converted into single index utility score between 0 to 1 that quantify health status, where 0 represents death and 1 represents perfect health.
Time frame: Baseline to Week 16
Population: Analysis was performed on ITT population.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo Q2W | Percentage Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire (EQ-5D) Index Scores | 2.92 percentage change | Standard Error 0.692 |
| Dupilumab 300 mg Q2W | Percentage Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire (EQ-5D) Index Scores | 8.00 percentage change | Standard Error 0.562 |
Secondary
Percentage Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire Visual Analog Scale Scores
The EQ-5D VAS records the respondent's self-rated health on a vertical, visual analogue scale ranged from 0-100 where 100 indicated best imaginable health state and 0 indicated worst imaginable health state, higher scores indicated better outcome.
Time frame: Baseline to Week 16
Population: Analysis was performed on ITT population.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo Q2W | Percentage Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire Visual Analog Scale Scores | 60.19 percentage change | Standard Error 25.154 |
| Dupilumab 300 mg Q2W | Percentage Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire Visual Analog Scale Scores | 90.32 percentage change | Standard Error 24.775 |
Secondary
Percentage Change From Baseline to Week 2 in Weekly Average of Peak Daily Pruritus NRS
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.
Time frame: Baseline to Week 2
Population: Analysis was performed on ITT population.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo Q2W | Percentage Change From Baseline to Week 2 in Weekly Average of Peak Daily Pruritus NRS | -4.75 percentage change | Standard Error 1.802 |
| Dupilumab 300 mg Q2W | Percentage Change From Baseline to Week 2 in Weekly Average of Peak Daily Pruritus NRS | -15.65 percentage change | Standard Error 1.818 |
Secondary
Percentage Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16
EASI: Measure to assess severity & extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] & lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of 0 (absent) through 3 (severe) & scored separately for each of 4 body regions (head, trunk, upper & lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Population: Analysis was performed on ITT population.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Q2W | Percentage Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16 | Week 4 | -19.28 percentage change | Standard Error 3.981 |
| Placebo Q2W | Percentage Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16 | Week 12 | -35.26 percentage change | Standard Error 4.674 |
| Placebo Q2W | Percentage Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16 | Week 8 | -29.38 percentage change | Standard Error 4.147 |
| Placebo Q2W | Percentage Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16 | Week 16 | -39.44 percentage change | Standard Error 4.936 |
| Placebo Q2W | Percentage Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16 | Week 2 | -10.55 percentage change | Standard Error 2.977 |
| Dupilumab 300 mg Q2W | Percentage Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16 | Week 16 | -75.23 percentage change | Standard Error 3.879 |
| Dupilumab 300 mg Q2W | Percentage Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16 | Week 2 | -35.69 percentage change | Standard Error 2.93 |
| Dupilumab 300 mg Q2W | Percentage Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16 | Week 4 | -55.83 percentage change | Standard Error 3.684 |
| Dupilumab 300 mg Q2W | Percentage Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16 | Week 8 | -65.84 percentage change | Standard Error 3.562 |
| Dupilumab 300 mg Q2W | Percentage Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16 | Week 12 | -70.36 percentage change | Standard Error 4.047 |
Secondary
Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity. Participants with missing peak NRS scores at each visit were imputed using MI method.
Time frame: From Baseline Through Week 16
Population: Analysis was performed on ITT population.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 1 | -2.95 percentage change | Standard Error 1.387 |
| Placebo Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 2 | -4.75 percentage change | Standard Error 1.802 |
| Placebo Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 3 | -7.92 percentage change | Standard Error 2 |
| Placebo Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 4 | -9.10 percentage change | Standard Error 2.118 |
| Placebo Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 5 | -11.56 percentage change | Standard Error 2.477 |
| Placebo Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 6 | -12.41 percentage change | Standard Error 2.623 |
| Placebo Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 7 | -11.37 percentage change | Standard Error 2.743 |
| Placebo Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 8 | -13.22 percentage change | Standard Error 2.71 |
| Placebo Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 9 | -14.03 percentage change | Standard Error 2.796 |
| Placebo Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 10 | -14.24 percentage change | Standard Error 2.857 |
| Placebo Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 11 | -15.72 percentage change | Standard Error 2.972 |
| Placebo Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 12 | -17.07 percentage change | Standard Error 3.048 |
| Placebo Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 13 | -18.80 percentage change | Standard Error 3.235 |
| Placebo Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 14 | -19.63 percentage change | Standard Error 3.501 |
| Placebo Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 15 | -19.96 percentage change | Standard Error 3.503 |
| Placebo Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 16 | -21.13 percentage change | Standard Error 3.61 |
| Dupilumab 300 mg Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 16 | -48.59 percentage change | Standard Error 3.026 |
| Dupilumab 300 mg Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 1 | -7.30 percentage change | Standard Error 1.405 |
| Dupilumab 300 mg Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 9 | -41.28 percentage change | Standard Error 2.655 |
| Dupilumab 300 mg Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 2 | -15.65 percentage change | Standard Error 1.818 |
| Dupilumab 300 mg Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 13 | -46.15 percentage change | Standard Error 2.845 |
| Dupilumab 300 mg Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 3 | -23.66 percentage change | Standard Error 1.988 |
| Dupilumab 300 mg Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 10 | -42.51 percentage change | Standard Error 2.682 |
| Dupilumab 300 mg Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 4 | -28.17 percentage change | Standard Error 2.069 |
| Dupilumab 300 mg Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 15 | -48.29 percentage change | Standard Error 3.009 |
| Dupilumab 300 mg Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 5 | -32.65 percentage change | Standard Error 2.41 |
| Dupilumab 300 mg Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 11 | -44.26 percentage change | Standard Error 2.746 |
| Dupilumab 300 mg Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 6 | -35.01 percentage change | Standard Error 2.543 |
| Dupilumab 300 mg Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 14 | -47.04 percentage change | Standard Error 3.061 |
| Dupilumab 300 mg Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 7 | -39.16 percentage change | Standard Error 2.642 |
| Dupilumab 300 mg Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 12 | -45.37 percentage change | Standard Error 2.735 |
| Dupilumab 300 mg Q2W | Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16 | Week 8 | -40.36 percentage change | Standard Error 2.594 |
Secondary
Percentage of Participants With at Least One Day Sick Leave/Missed School Days
Participants who were employed or enrolled in school for full time were asked to report the number of sick leave/missed school days since the last study assessment. Participants were counted as Full time if the participant checked Full time at all visits through 16-week treatment period and participants were counted as Part time if the participant checked at least one Part time during 16-week treatment period.
Time frame: Week 16
Population: Analysis was performed on ITT population. Here, 'overall number of participants analyzed' = participants with available data for this outcome measure and 'number analyzed' represent the number of participants analyzed for each specified row.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo Q2W | Percentage of Participants With at Least One Day Sick Leave/Missed School Days | Full time | 14.9 percentage of participants |
| Placebo Q2W | Percentage of Participants With at Least One Day Sick Leave/Missed School Days | Part time | 72.7 percentage of participants |
| Dupilumab 300 mg Q2W | Percentage of Participants With at Least One Day Sick Leave/Missed School Days | Full time | 22.4 percentage of participants |
| Dupilumab 300 mg Q2W | Percentage of Participants With at Least One Day Sick Leave/Missed School Days | Part time | 75.0 percentage of participants |